Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia

New England Journal of Medicine

Volumn 328, Issue 18, 1993, Pages 1323-1332

  Wood, Alastair J J ^a   Pizzo, Philip A ^b  

^a National Cancer Institute ^*

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; CYTOKINE; FLUCONAZOLE; FLUCYTOSINE; GANCICLOVIR; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN; INTERFERON; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PENTAMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ASPERGILLOSIS; CANCER PATIENT; CANCER SURVIVAL; CANDIDIASIS; DISEASE DURATION; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HERPES VIRUS INFECTION; HOST RESISTANCE; HUMAN; IMMUNE STATUS; INDWELLING CATHETER; INFECTION RISK; MYCOBACTERIUM; NEUTROPENIA; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; BACTERIAL INFECTION; IMMUNE DEFICIENCY; NEOPLASM;

ANTIBIOTICS; BACTERIAL INFECTIONS; CATHETERS, INDWELLING; FEVER; HEMATOPOIETIC CELL GROWTH FACTORS; HUMAN; IMMUNOCOMPROMISED HOST; NEOPLASMS; NEUTROPENIA;

EID: 0027289342     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199305063281808     Document Type: Review

References (117)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-340
2. Pizzo PA. Empirical therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990:2303-12.
3. Rubin M, Walsh TJ, Pizzo PA. Clinical approach to infections in the compromised host. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: basic principles and practice. New York: Churchill Livingstone, 1991:1063-114.
4. Pizzo PA, Rubin M, Freifeld A, Walsh TJ The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991; 119:679-694
5. Pizzo PA, Rubin M, Freifeld A, Walsh TJ The child with cancer and infection. II. Nonbacterial infections. J Pediatr 1991; 119:845-857
6. Schimpff SC Overview of empiric antibiotic therapy for the febrile neutropenic patient. Rev Infect Dis 1985; 7: Suppl 4: S734-S740
7. Pizzo PA Granulocytopenia and cancer therapy: past problems, current solutions, future challenges. Cancer 1984; 54: Suppl: 2649-2661
8. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77:707-714
9. Ladisch SL, Pizzo PA Staphylococcus aureus sepsis in children with cancer. Pediatrics 1978; 61:231-234
10. Klastersky J, Zinner SH Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982; 4:294-301
11. Young LS. Combination or single drug therapy for gram-negative sepsis. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Vol. 3. New York: McGraw-Hill, 1982:177-205.
12. Love LJ, Schimpff SC, Schiffer CA, Wiernik PH Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med 1980; 68:643-648
13. Bodey GP, Jadeja L, Elting L Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-1629
14. Pizzo PA, Robichaud KJ, Wesley R, Commers JA Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine (Baltimore) 1982; 61:153-165
15. Pizzo PA, Commers J, Cotton D, Approaching the controversies in the antibacterial management of cancer patients. Am J Med 1984; 76:436-449
16. Schiffer CA. Current status of granulocyte transfusion therapy. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Vol. 5. New York: McGraw-Hill, 1984:189-209.
17. Winston DJ, Ho WG, Howell CL, Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 1980; 93:671-675
18. Schiffer CA, Aisner J, Daly PA, Schimpff SC, Wiernik PH Alloimmunization following prophylactic granulocyte transfusion. Blood 1979; 54:766-774
19. Pizzo PA, Robichaud KJ, Gill FA, Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67:194-200
20. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101-111
21. Pizzo PA After empiric therapy: what to do until the granulocyte comes back. Rev Infect Dis 1987; 9:214-219
22. Walsh TJ, Pizzo PA. Fungal infections in granulocytopenic patients: current approaches to classification, diagnosis, and treatment. In: Holmberg K, Meyer RD, eds. Diagnosis and therapy of systemic fungal infections. New York: Raven Press, 1989:47-70.
23. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-672
24. Walsh TJ, Lee J, Lecciones J, Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991; 13:496-503
25. Pathogen-specific vs. broad-spectrum antibiotics for granulocytopenic cancer patients with proven infection, D., Cotton, D., Marshall, J., Gress, et al., Program and abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 8-10, 1984. Washington, D.C.: American Society for Microbiology, abstract., (1984), 158
26. Pizzo PA Considerations for the prevention of infectious complications in patients with cancer. Rev Infect Dis 1989; 11: Suppl 7: S1551-S1563
27. Pizzo PA. Antibiotic prophylaxis in the immunosuppressed patient with cancer. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Vol. 4. New York: McGraw-Hill, 1983:153-67.
28. Hughes WT, Armstrong D, Bodey GP, Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Disease Society of America. J Infect Dis 1990; 161:381-396 [Erratum, J Infect Dis 1990;161:1316.]
29. Pizzo PA, Ladisch S, Simon RM, Gill F, Levine AS Increasing incidence of Gram-positive sepsis in cancer patients. Med Pediatr Oncol 1978; 5:241-244
30. Dybedal I, Lamvik J Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans. Eur J Haematol 1989; 42:405-406
31. Karp JE, Merz WG, Hendricksen C, Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987; 106:1-7
32. Dekker AW, Rozenberg-Arska M, Verhoef J Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987; 106:7-12
33. Kotilainen P, Nikoskelainen J, Huovinen P Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990; 161:41-44
34. Chow JW, Fine MJ, Shlaes DM, Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-590
35. Roilides E, Butler KM, Husson RN, Mueller BU, Lewis LL, Pizzo PA Pseudomonas infections in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1992; 11:547-553
36. Glenn J, Cotton D, Wesley R, Pizzo PA Anorectal infections in patients with malignant diseases. Rev Infect Dis 1988; 10:42-52
37. Weinberger M, Wu T, Rubin M, Gill VJ, Pizzo PA Leptotrichia buccalis bacteremia in patients with cancer: report of four cases and review. Rev Infect Dis 1991; 13:201-206
38. Thaler M, Gill V, Pizzo PA Emergence of Clostridium tertium as a pathogen in neutropenic patients. Am J Med 1986; 81:596-600
39. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204-210
40. Flynn PM, Van Hooser B, Gigliotti F Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J 1988; 7:510-513
41. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324:1644-1650
42. Daley CL, Small PM, Schecter GF, An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231-235
43. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-1277
44. Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 1987; 83:17-26
45. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88-100
46. Thaler M, Bacher J, O'Leary T, Pizzo PA Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis 1988; 158:80-88
47. Lopez-Berestein G, Bodey GP, Fainstein V, Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149:2533-2536
48. Kauffman CA, Bradley SF, Ross SC, Weber DR Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91:137-141
49. Anaissie E, Bodey GP, Kantarjian H, Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91:142-150
50. Mullen CA, Buchanan GR Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 1990; 8:1998-2004
51. Weinberger M, Elattar I, Marshall D, Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71:24-43
52. Walsh TJ, Hathorn JW, Sobel JD, Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 1991; 324:1026-1031
53. Peter JB The polymerase chain reaction: amplifying our options. Rev Infect Dis 1991; 13:166-171
54. Pizzo PA Evaluation of fever in the patient with cancer. Eur J Cancer Clin Oncol 1989; 25: Suppl 2: S9-S16
55. Sickles EA, Greene WH, Wiernik PH Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715-719
56. 111In-labeled nonspecific immunoglobulin scanning in the detection of focal infection. N Engl J Med 1989; 321:935-940
57. Feusner J, Cohen R, O'Leary M, Beach B Use of routine chest radiography in the evaluation of fever in neutropenic oncology patients. J Clin Oncol 1988; 6:1699-1702
58. Barloon TJ, Galvin JR, Mori M, Stanford W, Gingrich RD High-resolution ultrafast chest CT in the clinical management of febrile bone marrow transplant patients with normal or nonspecific chest roentgenograms. Chest 1991; 99:928-933
59. Kramer BS, Pizzo PA, Robichaud KJ, Witebsky FG, Wesley R Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. Am J Med 1982; 72:561-568
60. Pizzo PA, Thaler M, Hathorn J, New β-lactam antibiotics in granulocytopenic patient: new options and new questions. Am J Med 1985; 79: Suppl 2A: 75-82
61. Freifeld A, Pizzo PA. New developments in the antimicrobial supportive care of the immunocompromised patient. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology updates. Vol. 5. Philadelphia: J.B. Lippincott, 1991:1-14.
62. Karp JE, Dick JD, Angelopulos C, Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986; 81:237-242
63. Pizzo PA, Hathorn JW, Hiemenz J, A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552-558
64. Huijgens PC, Ossenkoppele GJ, Weijers TF, Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies. Eur J Haematol 1991; 46:42-46
65. Sanders JW, Powe NR, Moore RD Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991; 164:907-916
66. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317:1692-1698
67. Winston DJ, Ho WG, Bruckner DA, Champlin RE β-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115:849-859
68. Shenep JL, Hughes WT, Roberson PK, Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319:1053-1058
69. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108:30-35
70. European Organization for Research and Treatment of Cancer (EORTC), International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163:951-958 [Erratum, J Infect Dis 1991;164:832.]
71. Novakova I, Donnelly JP, De Pauw B Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 1991; 35:672-678
72. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990; 161:397-401
73. Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986; 81:243-248
74. Neu HC The quinolones. Infect Dis Clin North Am 1989; 3:625-639
75. Patton WN, Smith GM, Leyland MJ, Geddes AM Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin. J Antimicrob Chemother 1985; 16:667-669
76. Trucksis M, Hooper DC, Wolfson JS Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991; 114:424-426
77. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized, double-blind, controlled trial in bone-marrow-transplant recipients. N Engl J Med 1981; 305:63-67
78. Meyers JD, Reed EC, Shepp DH, Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318:70-75
79. Schmidt GM, Horak DA, Niland JC, A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324:1005-1011
80. Merigan TC, Renlund DG, Keay S, A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326:1182-1186
81. Emanuel D, Cunningham I, Jules-Elysee K, Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109:777-782
82. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109:783-788
83. Navarro E, Lecciones JA, Lee JW, et al. Invasive pulmonary aspergillosis developing during empirical antifungal therapy in febrile cancer patients. Am J Med (in press).
84. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5:1985-1993
85. Goodman JL, Winston DJ, Greenfield RA, A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851
86. Cotton DJ, Gill VJ, Marshall DJ, Gress J, Thaler M, Pizzo PA Clinical features and therapeutic interventions in 17 cases of Bacillus bacteremia in an immunosuppressed patient population. J Clin Microbiol 1987; 25:672-674
87. Lecciones JA, Lee JW, Navarro EE, Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14:875-883
88. Schwartz C, Henrickson KJ, Roghmann K, Powell K Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 1990; 8:1591-1597
89. Mirro J Jr, Rao BN, Stokes DC, A prospective study of Hickman/ Broviac catheters and implantable ports in pediatric oncology patients. J Clin Oncol 1989; 7:214-222
90. Ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am J Pediatr Hematol Oncol 1991; 13:130-136
91. Mueller BU, Skelton J, Callender DP, A prospective randomized trial comparing the infectious and noninfectious complications of externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992; 10:1943-1948
92. Dinarello CA The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991; 163:1177-1184
93. Dinarello CA Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77:1627-1652
94. Groopman J, Molina J-M, Scadden D Hematopoietic growth factors: biology and clinical applications. N Engl J Med 1989; 321:1449-1459
95. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992; 10:1266-1277
96. Gasson JC Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77:1131-1145
97. Ziegler EJ, McCutchan JA, Fierer J, Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-1230
98. Ziegler EJ, Fisher CJ Jr, Sprung CL, Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
99. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324:509-516
100. Weeks JC, Tierney MR, Weinstein MC Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325:81-86
101. Prophylaxis of infectious complications in neutropenic cancer patients with intravenous immunoglobulin, M., Rubin, J., Gress, D., Marshall, et al., Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, October 23-26, 1988. Washington, D.C.: American Society for Microbiology, abstract., (1988), 608
102. Dwyer JM Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-116
103. Lieschke GJ, Burgess AW Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327:28-35, 99
104. Antman KS, Griffin JD, Elias A, Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319:593-598
105. Gabrilove JL, Jakubowski A, Scher H, Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318:1414-1422
106. Bronchud MH, Scarffe JH, Thatcher N, Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56:809-813
107. Brandt SJ, Peters WP, Atwater SK, Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869-876
108. Nemunaitis J, Rabinowe SN, Singer JW, Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773-1778
109. Nemunaitis J, Meyers JD, Buckner CD, Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78:907-913
110. Roilides E, Pizzo PA Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992; 15:508-524
111. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte colony-stimulating factor and interferon-gamma. J Infect Dis 1992; 166:668-673
112. Roilides E, Walsh TJ, Pizzo PA, Rubin M Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991; 163:579-583
113. Talcott JA, Siegel RD, Finberg R, Goldman L Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316-322
114. Duhrsen U, Villeval J-L, Boyd J, Kannourakis G, Morstyn G, Metcalf D Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72:2074-2081
115. Socinski MA, Cannistra S, Elias A, Antman KH, Schnipper L, Griffin JD Granulocyte-macrophage colony stimulating factor expands the circulating haematopoietic progenitor cell compartment in man. Lancet 1988; 1:1194-1198
116. Peters W, Kurtzberg J, Kirkpatrick G, GM-CSF primed peripheral blood progenitor cells coupled with autologous bone marrow transplantation will eliminate absolute leukopenia following high dose chemotherapy. Blood 1989; 74: Suppl 1: 50a-50a abstract.
117. Haas R, Ho AD, Bredthauer U, Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990; 18:94-98